Fig. 2From: A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imagingPercentage change from baseline to day 14 in median FES uptake for individual patients in the intention-to-treat population. One patient who had < − 100% change (i.e., > 100% reduction) was included as −100%. Response per RECIST (PR, SD, PD, NE) for each patient and patients with CBR at 24 weeks (†) are noted. FES, 16α-18F-fluoro-17β-estradiolBack to article page